HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via ISI Web of Science (3) Citing Articles via Google Scholar Google Scholar Articles by Noveck, R. J. Articles by Hubbard, R. C. Search for Related Content PubMed PubMed Citation Articles by Noveck, R. J. Articles by Hubbard, R. C. Social Bookmarking                   What's this?

Parecoxib Sodium, an Injectable COX-2-Specific Inhibitor, Does Not Affect Unfractionated Heparin-Regulated Blood Coagulation Parameters

From the Clinical Research Center, New Orleans, Louisiana (Dr. Noveck) and Pfizer Global Pharmaceuticals, Ann Arbor, Michigan (Dr. Hubbard).

The objective of this study was to evaluate the potential for hemostatic interaction between a full analgesic dose of parecoxib sodium (parecoxib), a prodrug of the COX-2 specific inhibitor valdecoxib, and unfractionated heparin (UFH) in healthy male subjects. This open-label, single-center study comprised two treatment periods. In treatment period I, fasted, eligible subjects (n = 18) received a UFH bolus (4000 U) followed by a 36-hour UFH infusion (start dose 10-14 U/kg). Activated partial thromboplastin time (aPTT), prothrombin time (PT), and platelet counts were measured at regular intervals up to 24 hours after the end of the UFH infusion. After a 2-day washout, patients randomized to treatment period II received a full analgesic dosage of parecoxib 40 mg bid intravenously (IV) for 6 days (n = 18), with concomitant UFH (same regimen as treatment period I) on day 5 (n = 18). APTT, PT, and platelet counts were evaluated at regular intervals up to 24 hours after UFH infusion. Coadministration of parecoxib 40 mg bid IV with UFH (treatment period II) had no significant effect on aPTT, PT, or platelet counts, which were similar to those of participants receiving UFH alone (treatment period I) at all time points. These results show that a full analgesic dose of parecoxib, a COX-2-specific inhibitor available for parenteral administration, can be coadministered with UFH without affecting blood coagulation parameters. Therefore, parecoxib may be administered to patients who are receiving UFH for thromboprophylaxis.

Key Words: Parecoxib sodium • COX-2-specific inhibitor • drug interaction • heparin • UFH • LMWH

Address for reprints: Richard C. Hubbard, MD, Executive Director, Pfizer Global Research and Development, Ann Arbor Laboratories, Ann Arbor, MI 48104.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?